Skip to main content

Luisa Ibáñez Mora

Institutions of which they are part

Clinical Pharmacology
Vall Hebron Institut de Recerca

Research lines

PROTECT (Pharmacoepidemiological Research on Outcome of Therapeutics by a European ConsorTium

The goal of this project is to strengthen the monitoring of benefit-risk of medicines in Europe by developing innovative methods that will enhance the early detection and assessment of adverse drug reaction from different data sources (clinical trials, spontaneous reporting and observational studies). Our group is responsible for working on the use of national drug utilisation data. The specific tasks are to build and update an inventory of data sources on the consumption of the medicines of interest, to evaluate and disseminate methodologies for drug utilisation studies in order to estimate the potential public health impact of adverse drug reactions.

IP: Luisa Ibáñez Mora

Projects

El uso de antidepresivos y su asociación con ictus, frecuencia de hospitalizaciones y mortalidad, en la población anciana

IP: Luisa Ibáñez Mora
Collaborators: Xavier Vidal Guitart, Maria Elena Ballarin Alins, Antonio San Jose Laporte, Olga Maisterra Santos, Mònica Sabaté Gallego, Lina Fernanda Camacho Arteaga
Funding agency: Instituto de Salud Carlos III
Funding: 45375
Reference: PI15/01429
Duration: 01/01/2016 - 30/11/2020

Factors genètics com determinants de risc d'hepatotoxicitat associats a l'ús de medicaments International Drug-Induced Liver Injury Consortium (IDILIC).

IP: Luisa Ibáñez Mora
Collaborators: -
Funding agency:
Funding:
Reference: PR(SC)327/2012
Duration: -

Determinantes genéticos en la agranulocitosis asociada al uso de medicamentos: un estudio de casos y controles

IP: Luisa Ibáñez Mora
Collaborators: Mònica Sabaté Gallego, Consuelo Pedrós Cholvi, Lourdes Vendrell Bosch
Funding agency: Instituto de Salud Carlos III
Funding: 182710
Reference: PI10/02632
Duration: 01/01/2011 - 31/12/2014

Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio exploratorio

IP: Luisa Ibáñez Mora
Collaborators: Xavier Vidal Guitart, Jaume Reventós Puigjaner, Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio expl, Maria Buti Ferret, Xavier Martínez Gómez, Teresa Soriano Sánchez, Israel Molina Romero, Eulàlia Pérez Esquirol, Mònica Sabaté Gallego, Maria Urquizu Padilla, Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio expl, Magda Campins Martí
Funding agency: Instituto de Salud Carlos III
Funding: 150645
Reference: EC08/00250
Duration: 01/01/2009 - 31/12/2012

Related news

The study by physician Emilie Anderssen seeks to optimize the medicalization of people living in nursing homes.

Related professionals

Rosa Burgos Peláez

Rosa Burgos Peláez

Read more
Meritxell Jiménez Llahí

Meritxell Jiménez Llahí

Read more
Montse Martinez Muñoz

Montse Martinez Muñoz

Read more
Cristina Dopazo Taboada

Cristina Dopazo Taboada

Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.